The online home for the primary care professionals managing patients with cardiovascular disease, diabetes and related diseases.

NICE recommends dapagliflozin in triple therapy for type 2 diabetes

NICE recommends dapagliflozin in triple therapy for type 2 diabetes

Publication date: Wednesday, 04 January 2017
Contributor(s): Jeremy Bray

The SGLT2 inhibitor dapagliflozin is now recommended by NICE as part of triple therapy with metformin and a sulfonylurea when two drugs for type 2 diabetes are not providing glycaemic control.

Professor Carole Longson, director of the NICE centre for health technology evaluation, said, “Having a range of drug options makes it easier to tailor treatments for type 2 diabetes to each person’s individual needs.  This new guidance recommends dapagliflozin in triple therapy – only in combination with metformin and a sulfonylurea – which will widen the choice available for people whose diabetes isn’t well controlled with two drugs.  And as we’ve been able to publish this final guidance sooner because of positive draft recommendations, we hope that people who need this extra treatment option will benefit more quickly.”

This final guidance means that dapagliflozin joins empagliflozin and canagliflozin as NICE-recommended options for triple therapy in type 2 diabetes. All three drugs are already recommended for use on their own if a person cannot use metformin or other specific drugs, or in combination with metformin as dual therapy.

More information

Dapagliflozin in triple therapy regimens for treating type 2 diabetes (TA 418), 23 November 2016

Topics covered:
Category: Have You Heard
Edition: Volume 1 Number 12 PCCJ Online 2016
Contributor(s): Jeremy Bray

Article search and filter